Frontiers in Diabetic Macular Edema: Durable Suppression for Addressing Health Disparities - a podcast by ReachMD

CME credits: 0.25

Valid until: 21-05-2022

Claim your CME credit at https://reachmd.com/programs/cme/frontiers-diabetic-macular-edema-durable-suppression-addressing-health-disparities/12568/

Diabetic macular edema (DME) remains undertreated in the real world. New targeted agents are in development for DME that seek to broaden current treatment approaches while improving upon the durability of VEGF suppression. These new treatments that go beyond the current standard of care may help reduce treatment burdens and ultimately improve vision outcomes in DME. Join our two experts, Dr. Christina Weng and Dr. Arshad Khanani, as they discuss these emerging agents, their mechanisms of action, and the latest available data.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD